[go: up one dir, main page]

CL2016000387A1 - Derivados de amida como antagonistas de ácido receptor lisofosfatidico - Google Patents

Derivados de amida como antagonistas de ácido receptor lisofosfatidico

Info

Publication number
CL2016000387A1
CL2016000387A1 CL2016000387A CL2016000387A CL2016000387A1 CL 2016000387 A1 CL2016000387 A1 CL 2016000387A1 CL 2016000387 A CL2016000387 A CL 2016000387A CL 2016000387 A CL2016000387 A CL 2016000387A CL 2016000387 A1 CL2016000387 A1 CL 2016000387A1
Authority
CL
Chile
Prior art keywords
antagonists
acid receptor
amide derivatives
lysophosphatidic acid
lisophosphytidic
Prior art date
Application number
CL2016000387A
Other languages
English (en)
Inventor
William Buffham
Hannah Canning
Richard Davenport
William Farnaby
Stephen Mack
Alka Parmar
Susanne Wright
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2016000387A1 publication Critical patent/CL2016000387A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPUESTOS DERIVADOS DE AMIDA, ANTAGONISTAS DEL RECEPTOR DEL ACIDO LISOFOSFATIDICO; PROCESO DE PREPARACION; COMPOSICION FARMACEUTICA; USO EN EL TRATAMIENTO DE TRASTORNOS DEL DOLOR, ATEROESCLEROSIS O FIBROSIS.
CL2016000387A 2013-08-20 2016-02-19 Derivados de amida como antagonistas de ácido receptor lisofosfatidico CL2016000387A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1314926.5A GB201314926D0 (en) 2013-08-20 2013-08-20 Novel Compounds

Publications (1)

Publication Number Publication Date
CL2016000387A1 true CL2016000387A1 (es) 2016-12-16

Family

ID=49301993

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000387A CL2016000387A1 (es) 2013-08-20 2016-02-19 Derivados de amida como antagonistas de ácido receptor lisofosfatidico

Country Status (24)

Country Link
US (3) US9464060B2 (es)
EP (1) EP3036215A1 (es)
JP (1) JP6422974B2 (es)
KR (1) KR20160045797A (es)
CN (1) CN105473548B (es)
AR (1) AR097403A1 (es)
AU (1) AU2014310404B2 (es)
CA (1) CA2921742A1 (es)
CL (1) CL2016000387A1 (es)
CR (1) CR20160084A (es)
EA (1) EA028818B1 (es)
GB (1) GB201314926D0 (es)
HK (1) HK1225712A1 (es)
IL (1) IL243780A0 (es)
MA (1) MA38854B1 (es)
MX (1) MX2016001896A (es)
PE (1) PE20160284A1 (es)
PH (1) PH12016500322A1 (es)
SG (1) SG11201601250TA (es)
TN (1) TN2016000061A1 (es)
TW (1) TW201536722A (es)
UY (1) UY35708A (es)
WO (1) WO2015025164A1 (es)
ZA (1) ZA201600753B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN119823001A (zh) 2019-07-30 2025-04-15 大正制药株式会社 拮抗lpa1受体的脲化合物
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2024252334A1 (en) * 2023-06-06 2024-12-12 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707641B1 (fr) * 1993-07-16 1995-08-25 Fournier Ind & Sante Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
TW200400930A (en) 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
MX2012003560A (es) 2009-09-25 2012-10-05 Astellas Pharma Inc Compuesto de amida sustituida.
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
GB201314926D0 (en) * 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds

Also Published As

Publication number Publication date
UY35708A (es) 2014-12-31
CA2921742A1 (en) 2015-02-26
AR097403A1 (es) 2016-03-09
TN2016000061A1 (en) 2017-07-05
AU2014310404B2 (en) 2018-07-12
CN105473548A (zh) 2016-04-06
SG11201601250TA (en) 2016-03-30
IL243780A0 (en) 2016-04-21
CN105473548B (zh) 2018-03-23
JP6422974B2 (ja) 2018-11-14
ZA201600753B (en) 2019-07-31
EA028818B1 (ru) 2018-01-31
PE20160284A1 (es) 2016-04-27
US20160207880A1 (en) 2016-07-21
KR20160045797A (ko) 2016-04-27
MA38854A1 (fr) 2017-07-31
WO2015025164A1 (en) 2015-02-26
MA38854B1 (fr) 2018-05-31
TW201536722A (zh) 2015-10-01
MX2016001896A (es) 2016-05-26
AU2014310404A1 (en) 2016-03-10
EA201690390A1 (ru) 2016-08-31
PH12016500322A1 (en) 2016-05-02
US10100018B2 (en) 2018-10-16
GB201314926D0 (en) 2013-10-02
US9464060B2 (en) 2016-10-11
US20190010129A1 (en) 2019-01-10
CR20160084A (es) 2016-05-27
JP2016528274A (ja) 2016-09-15
EP3036215A1 (en) 2016-06-29
HK1225712A1 (zh) 2017-09-15
US20150057298A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CO2017000886A2 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carbox-amida y su purificación para su uso como principio activo farmacéutico
CL2016001895A1 (es) Compuestos
MX380777B (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MY193728A (en) Muscarinic receptor agonists
NZ766530A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX387228B (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos.
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
MX373652B (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2018002027A (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico.
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
PH12017500089B1 (en) Aldosterone synthase inhibitors
CL2016002839A1 (es) Derivados de carboxamida
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
TW201613884A (en) Selective NR2B antagonists
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
PH12017500595B1 (en) Aldosterone synthase inhibitors